I. Why do we need regular review and follow up? Metastasis and recurrence are the basic characteristics of malignant tumors, and cancer is prone to recurrence and metastasis. 20% of stage I non-small cell lung cancer patients have recurrence or metastasis after surgery, 30-50% of stage II, and over 50% of stage III. In order to obtain longer survival time and higher quality of life, therefore, we require lung cancer patients to have regular review and follow up. Lu Kaihua, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University What are the benefits of regular review and follow-up? 1.It helps to detect micro lesion metastasis, early detection and early treatment. 2.Establishing systematic files helps doctors to understand the disease comprehensively and provide guidance basis for later treatment. 3.It helps patients to get the latest progress of lung cancer treatment from doctors in time, so that they can receive the treatment of new technology and new drugs at the first time. How to conduct regular review and follow up? 1.Post-operative patients: Post-operative baseline examination is the basis for judging recurrence and metastasis in the future and must be performed, preferably within 1 month after surgery, including medical history, physical examination, blood routine, biochemistry, tumor markers (CEA, NSE, CY211), direct-enhanced CT examination of chest, upper abdomen scan + direct-enhanced CT examination, cranial MR examination, whole body bone scan (cranial MR and whole body bone scan). bone scan examination if already done before surgery (no more than 2 months) can be considered not to be done). Postoperative year 1-2: monthly CEA, CYF211, NSE; every 3 months direct-enhanced CT of the chest, upper abdominal scan + direct-enhanced CT; every 6 months cranial MR, whole-body bone scan. From the 3rd year after surgery: CEA, CYF211, NSE, direct-enhanced CT of the chest, upper abdominal scan + direct-enhanced CT examination, cranial MR, whole-body bone scan every 6-12 months. 2. Advanced patients: After chemotherapy: monthly check of tumor markers CEA, CYF211, NSE; every 3 months, direct-enhanced CT of the chest, upper abdominal scan + direct-enhanced CT examination and imaging examinations related to metastases; every 6 months, cranial MR, whole-body bone scan.